There are increased clinical trials interrogating the efficacy of PD-L1 inhibitors (Table 2), both as single agents and in combination with existing treatments, in aggressive or relapsed/refractory T cell lymphoma (NCT03075553, NCT02631746 (Rauch et al. 2019), NCT03011814, NCT03161223 and NCT03046953, Table 2). The gene discussed is CD274; the disease is T-cell non-Hodgkin lymphoma.